AR120059A1 - Métodos y composiciones para mejorar resultados de pacientes con cáncer - Google Patents
Métodos y composiciones para mejorar resultados de pacientes con cáncerInfo
- Publication number
- AR120059A1 AR120059A1 ARP200101665A ARP200101665A AR120059A1 AR 120059 A1 AR120059 A1 AR 120059A1 AR P200101665 A ARP200101665 A AR P200101665A AR P200101665 A ARP200101665 A AR P200101665A AR 120059 A1 AR120059 A1 AR 120059A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- pharmaceutical grade
- subject
- pharmaceutical
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un método para prevenir, aliviar o tratar una enfermedad o afección relacionada con la hipoxia, que comprende administrar una cantidad efectiva de una composición a un sujeto que necesita de ello para mejorar el transporte de oxígeno y de ese modo elevar los niveles de oxígeno en sangre, en donde la composición comprende: por lo menos un ácido de grado farmacéutico y por lo menos un agente regulador del pH en una solución acuosa estéril, en donde la concentración del ácido de grado farmacéutico y el agente regulador del pH de grado farmacéutico en la solución de tampón es suficiente para proporcionar un contenido de ácido titulable total de entre 60 mmol/l y 3000 mmol/l cuando se administra a un sujeto y cuando la selección del ácido de grado farmacéutico y el agente regulador del pH de grado farmacéutico es efectiva para proporcionar un pH de la solución de tampón de entre 4,0 y 7,7. Reivindicación 4: El método de acuerdo con una cualquiera de las reivindicaciones precedentes, en donde el cáncer se selecciona del grupo que consiste en cáncer de mama, cáncer pancreático, cáncer de ovarios, cáncer de colon, cáncer pulmonar, cáncer pulmonar de células no pequeñas, carcinoma in situ (ISC), carcinoma de células escamosas (SCC), cáncer de tiroides, cáncer de cuello uterino, cáncer de útero, cáncer de próstata, cáncer testicular, cáncer de cerebro, cáncer de vejiga, cáncer de estómago, hepatoma, melanoma, glioma, retinoblastoma, mesotelioma, mieloma, linfoma y leucemia. Reivindicación 9: Un método para tratar a un sujeto que padece una enfermedad caracterizada por el calcio en suero elevado, que comprende administrar al sujeto una cantidad efectiva de una composición para reducir los niveles de calcio en sangre, en donde la composición comprende: por lo menos un ácido de grado farmacéutico y por lo menos un agente regulador del pH de grado farmacéutico en una solución acuosa estéril, en donde la concentración del ácido de grado farmacéutico y agente regulador del pH de grado farmacéutico en la solución de tampón es suficiente para proporcionar un contenido de ácido titulable total de entre 60 mmol/l y 3000 mmol/l cuando se administra a un sujeto y en donde la selección del ácido de grado farmacéutico y el agente regulador del pH de grado farmacéutico es efectiva para proporcionar un pH de la solución de tampón de entre 4,0 u 7,7. Reivindicación 11: Un método para suprimir la agresión de un tumor en un sujeto que tiene cáncer mientras se restaura la angiogénesis en el tejido sano del sujeto, que comprende administrar al sujeto una cantidad efectiva de una composición para aumentar eNOS y suprimir iNOS, en donde la composición comprende: por lo menos un ácido de grado farmacéutico y por lo menos un agente regulador del pH de grado farmacéutico en una solución acuosa estéril, en donde la concentración del ácido de grado farmacéutico y el agente regulador del pH de grado farmacéutico en la solución de tampón es suficiente para proporcionar un contenido de ácido titulable total de entre 60 mmol/l y 3.000 mmol/l cuando se administra a un sujeto y en donde la selección del ácido de grado farmacéutico y el agente regulador del pH de grado farmacéutico es efectiva para proporcionar un pH de la solución de entre 4,0 y 7.7.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860642P | 2019-06-12 | 2019-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120059A1 true AR120059A1 (es) | 2022-02-02 |
Family
ID=73745688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101665A AR120059A1 (es) | 2019-06-12 | 2020-06-12 | Métodos y composiciones para mejorar resultados de pacientes con cáncer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200390743A1 (es) |
| EP (1) | EP3982947A1 (es) |
| JP (1) | JP2022536708A (es) |
| KR (1) | KR20220029657A (es) |
| CN (1) | CN114222566A (es) |
| AR (1) | AR120059A1 (es) |
| AU (1) | AU2020293232A1 (es) |
| BR (1) | BR112021025105A2 (es) |
| CA (1) | CA3141418A1 (es) |
| EA (1) | EA202290027A1 (es) |
| IL (1) | IL288787A (es) |
| MX (1) | MX2021015228A (es) |
| TW (1) | TW202112358A (es) |
| WO (1) | WO2020252238A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
| US20230135127A1 (en) * | 2021-10-28 | 2023-05-04 | Wei-ping Zeng | Compositions and methods for disease treatment and prevention by ph modifiers and/or cell proliferation inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135948A (en) * | 1988-11-21 | 1992-08-04 | Norsk Hydro A.S. | Pharmaceutical compositions with anti-cancer activity against carcinoma and method for the treatment of carcinoma |
| EP1191948A2 (en) * | 1999-06-11 | 2002-04-03 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| US20040110684A1 (en) * | 1999-08-02 | 2004-06-10 | Universite Catholique De Louvain | Novel pharmaceutical compositions for modulating angiogenesis |
| WO2005044176A2 (en) * | 2003-11-10 | 2005-05-19 | Lipogen Ltd. | Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same |
| CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
| JP4611444B2 (ja) * | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| US20100087370A1 (en) * | 2007-02-14 | 2010-04-08 | The General Hospital Corporation | Modulation of nitric oxide signaling to normalize tumor vasculature |
| CA2806208C (en) * | 2010-07-22 | 2018-02-13 | Zishan Haroon | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
| JP6554099B2 (ja) * | 2013-08-07 | 2019-07-31 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | ｐ５３変異体を再活性化することの可能なペプチド |
-
2020
- 2020-06-12 TW TW109119962A patent/TW202112358A/zh unknown
- 2020-06-12 US US16/899,699 patent/US20200390743A1/en active Pending
- 2020-06-12 AU AU2020293232A patent/AU2020293232A1/en not_active Abandoned
- 2020-06-12 CA CA3141418A patent/CA3141418A1/en not_active Abandoned
- 2020-06-12 EA EA202290027A patent/EA202290027A1/ru unknown
- 2020-06-12 AR ARP200101665A patent/AR120059A1/es unknown
- 2020-06-12 EP EP20823685.1A patent/EP3982947A1/en not_active Withdrawn
- 2020-06-12 WO PCT/US2020/037398 patent/WO2020252238A1/en unknown
- 2020-06-12 MX MX2021015228A patent/MX2021015228A/es unknown
- 2020-06-12 CN CN202080057193.8A patent/CN114222566A/zh active Pending
- 2020-06-12 BR BR112021025105A patent/BR112021025105A2/pt not_active IP Right Cessation
- 2020-06-12 KR KR1020227000957A patent/KR20220029657A/ko unknown
- 2020-06-12 JP JP2021573502A patent/JP2022536708A/ja active Pending
-
2021
- 2021-12-08 IL IL288787A patent/IL288787A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220029657A (ko) | 2022-03-08 |
| TW202112358A (zh) | 2021-04-01 |
| CN114222566A (zh) | 2022-03-22 |
| WO2020252238A1 (en) | 2020-12-17 |
| MX2021015228A (es) | 2022-02-10 |
| US20200390743A1 (en) | 2020-12-17 |
| EA202290027A1 (ru) | 2022-03-29 |
| AU2020293232A1 (en) | 2022-02-03 |
| EP3982947A1 (en) | 2022-04-20 |
| BR112021025105A2 (pt) | 2022-03-15 |
| IL288787A (en) | 2022-02-01 |
| CA3141418A1 (en) | 2020-12-17 |
| JP2022536708A (ja) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120059A1 (es) | Métodos y composiciones para mejorar resultados de pacientes con cáncer | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| Qu et al. | Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1 | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| BR112018005494A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença. | |
| MD2849G2 (ro) | Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată | |
| Ranieri et al. | Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel | |
| Tang et al. | Effects of hyperbaric oxygen therapy on tumor growth in murine model of PC-3 prostate cancer cell line | |
| MX2022008632A (es) | Agente de union a ccr5 para el tratamiento de cancer metastasico positivo para ccr5. | |
| CO2022007910A2 (es) | Tratamientos contra el cáncer dirigidos a las células madre cancerosas | |
| BR112018015448A2 (pt) | conjugado anticorpo-fármaco, composição farmacêutica, métodos para liberar um agente ativo, para tratar uma doença, para inibir progressão de tumor e para inibir, diminuir ou eliminar a capacidade metastática de um tumor, e, kit. | |
| CN204317517U (zh) | 孕妇双效高腰托腹内裤 | |
| MX2021006548A (es) | Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica. | |
| CN101984967A (zh) | 用于治疗肿瘤的锰卟啉-二氯乙酸联合用药物 | |
| CN101601669B (zh) | 用于治疗肿瘤的联合用药物 | |
| WO2008121029A3 (en) | Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system | |
| Alturky et al. | Mastectomy for Women with Breast Cancer, Types and Considerations | |
| CN102028948B (zh) | 用于治疗肿瘤的锰卟啉-烷化剂联合用药物 | |
| Wang et al. | Ursodeoxycholic acid induces autophagy via LC3B to suppress hepatocellular carcinoma in vivo and in vitro | |
| CN105218647A (zh) | Vegfr2阻断剂多肽及其应用 | |
| CN102000070A (zh) | 用于治疗肿瘤的锰卟啉-氯尼达明联合用药物 | |
| Kirik et al. | Effects of hyperbaric oxygenation on subependymal microglia of the rat brain | |
| Zlatarova et al. | State of patient safety culture in Bulgaria: a literature review | |
| BR112022005980A2 (pt) | Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto |